pyridinolcarbamate has been researched along with Diabetic Glomerulosclerosis in 3 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camerini-Davalos, RA | 3 |
| Reddi, AS | 3 |
| Ehrenreich, TH | 1 |
| Strugatz, LH | 1 |
| Oppermann, W | 3 |
| Chen, M | 1 |
| Velasco, CA | 1 |
3 other studies available for pyridinolcarbamate and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Diabetic glomerulosclerosis in KK mice and its prevention by glyburide and pyridinolcarbamate.
Topics: Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose | 1979 |
Diabetic microangiopathy in KK mice. IV. Effect of pyridinolcarbamate on kidney glucosyltransferase activity and glomerulosclerosis.
Topics: Animals; Carbamates; Diabetic Nephropathies; Glucosyltransferases; Kidney; Kidney Cortex; Mice; Pyri | 1978 |
Diabetic microangiopathy in KK mice. II. Suppression of Glomerulosclerosis by pyridinolcarbamate.
Topics: Animals; Body Weight; Carbamates; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glucose; Glu | 1977 |